Addressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA

In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.

Terms & Conditions

EHA Meetings

Chairs and Members

ChairUwe Platzbecker, University of Leipzig, Medical Faculty, Clinic and Polyclinic for Hematology, Cellular Therapy and Hemostaseology (Germany)

Co-chairLionel Adès, Hôpital Saint-Louis Paris, Hématologie Seniors (France)

SWG Steering Committee
Pierre Fenaux, Hôpital Saint-Louis, Hématologie Seniors, Paris (France)
Arjan van de Loosdrecht, Amsterdam UMC, Hematology (The…

Abstracts & awards

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Look back at EHA2024